Macular Dystrophy: Types, Genetic Testing, Treatment, and Where Integrative Care Fits

In short. Macular dystrophies are inherited conditions that damage the macula, the central part of the retina used for reading and faces. Stargardt disease is the most common, and many types start in childhood or early adult life. They are not the same as age-related macular degeneration. Genetic testing usually confirms the type, and in the US it can be free. For most types there is no approved treatment yet, so care means protecting the retina, treating complications, low-vision support and clinical trials. Integrative care can sit alongside this plan but does not replace it.

What macular dystrophy is. Each macular dystrophy is caused by a change in a single gene. Most affect both eyes in a similar way and cause slow loss of central vision [1]. Stargardt disease affects about 1 in 8,000 to 10,000 people and is the most common macular dystrophy in both adults and children [1, 2].

Symptoms include blurred central vision, trouble reading or recognising faces, glare, and changes in colour vision. Side vision often stays useful. Diagnosis uses a dilated exam, OCT scans, autofluorescence photographs, electroretinography (ERG, a test of how the retina responds to light) and genetic testing.

Genetic testing matters because many types look alike. In a US series of 1,000 families with inherited retinal disease, testing found the cause in 76% [3]. Changes in ABCA4, the Stargardt gene, were the most common.

Main types.

• Stargardt disease (ABCA4). Inherited from both parents, who usually carry one gene change each without symptoms. It most often starts in childhood, and earlier onset tends to mean more severe vision loss [1].
• Best disease (BEST1). The second most common, often starting in childhood or the teens [1]. See Best disease.
• Pattern dystrophy (PRPH2). Usually starts later in adult life and has a good outlook, and it can be mistaken for macular degeneration [1]. See pattern dystrophy.
• X-linked retinoschisis (RS1). The most common juvenile-onset retinal degeneration in teenage boys, in which the retinal layers split [1].
• Cone and cone-rod dystrophy. About 1 in 40,000 people. It causes light sensitivity and poor colour vision first, and later night and side vision loss [4].
• North Carolina macular dystrophy. A rare condition in which the macula does not develop normally, linked to changes near the PRDM13 gene [5].
• Sorsby fundus dystrophy (TIMP3). Vision often drops in the 40s, from atrophy or leaking new blood vessels [1].
• Occult macular dystrophy (RP1L1). Central vision drops but the retina looks normal on examination, so it is easily missed [6]. Focal or multifocal ERG shows the problem [6].

Treatments with good evidence

Genetic testing and counselling. A confirmed gene result names the condition, shows how it is inherited, and is usually needed to join a trial. In the US, the Foundation Fighting Blindness runs the My Retina Tracker Genetic Testing Program [7]. It offers no-cost testing and genetic counselling to people clinically diagnosed with an inherited retinal disease, ordered by any US eye care professional. You can also choose to join its registry, which helps researchers find trial participants [7].

Treating complications. Leaking new vessels in Sorsby, Best and pattern dystrophy are treated with anti-VEGF injections, and early treatment matters [1]. In X-linked retinoschisis, carbonic anhydrase inhibitor drops or tablets can shrink the cysts. In one series of 36 patients, cysts reduced in 66% of eyes, though the average vision gain was less than one line [8].

Low-vision rehabilitation. This includes magnifiers, lighting, reading strategies and phone or tablet tools. The LOVIT trial enrolled 126 veterans with macular disease and vision between 20/100 and 20/500 [9]. After a rehabilitation programme they improved in reading and every other area tested, compared with a waiting list [9]. Children can get school vision services and classroom support.

Treatments with some evidence

Avoid vitamin A supplements in Stargardt disease. In mice lacking the ABCA4 gene, vitamin A supplements greatly increased the toxic pigment (lipofuscin) that builds up in Stargardt disease [10]. The authors concluded that vitamin A supplements should be avoided with ABCA4 changes, and specialists give the same advice [2, 10]. The original AREDS eye-vitamin formula contains 15 mg of beta-carotene, which the body turns into vitamin A [11]. Check labels, and ask your specialist before taking any eye vitamin that lists vitamin A or beta-carotene.

Sun protection. Bright light also sped up retinal damage in ABCA4 mice [2]. People with Stargardt disease are therefore often advised to wear UVA/UVB-blocking sunglasses and avoid long exposure to bright sun [2]. This is a precaution: the evidence in people is a small study of 5 patients [2]. Blue-light glasses for screens have not been tested in macular dystrophy.

Treatments in trials (not approved). None of these is available outside a trial.

• Gildeuretinol (ALK-001). This is a modified ("deuterated") form of vitamin A designed to form fewer toxic by-products. In the TEASE-1 trial of 50 people with Stargardt disease, atrophy grew 21.6% more slowly than in untreated comparison eyes over 2 years [12]. Against placebo alone the reduction was 14.9%, and the authors say its clinical value is not yet known [12]. A larger phase 3 trial, NORTHSTAR, started in June 2026 for about 230 people aged 8 to 45 [13].
• Tinlarebant. This daily pill lowers the protein that carries vitamin A to the eye [14]. In the phase 3 DRAGON trial of 104 people aged 12 to 20, lesions grew 35.7% more slowly than with placebo over 2 years [14]. These are company results, not yet peer reviewed. Side effects included a yellow tint to vision and slower adjustment to the dark [14]. The FDA accepted the application for priority review in August 2026, with a decision due by 12 February 2027 [15].
• Emixustat. The phase 3 SeaSTAR trial of 194 people did not meet its main goal of slowing atrophy, announced in October 2022 [16].

What is not proven

• Acupuncture and herbal medicine. We have not found trials of acupuncture, Chinese herbs or Ayurvedic herbs in any macular dystrophy. Small studies exist only in retinitis pigmentosa, and most lack proper controls.
• Supplements sold for "macular health". None has been shown to slow a macular dystrophy. DHA (fish oil) made no difference to macular function in a small Stargardt trial of 11 people [17]. Saffron did not improve vision in a pilot trial of 31 people, though it caused no harm [18].
• Paid "stem cell" injections outside regulated trials. Three people became severely and permanently visually impaired after eye injections at a US stem-cell clinic [19].
• Anything that asks you to skip genetic testing, monitoring or injections for leaking vessels.

Where Netra fits

Netra Eye Institute is an acupuncture and Oriental medicine practice. We do not diagnose or treat macular dystrophy, and we do not replace your retina specialist, genetic counsellor or low-vision team. Our role is adjunctive:

• We check the basics with your doctors: a genetic diagnosis, a monitoring plan, a low-vision referral and, if you wish, trial options.
• We offer acupuncture and, where appropriate, Chinese herbal medicine within Netra Restoration Therapy (NRT), with the evidence explained before you start. Herbs are reviewed against your medicines.
• If you have Stargardt disease, we check every herbal product and supplement for vitamin A, retinol or beta-carotene. We do not give products that contain them.
• We share what we see with your eye doctor. We refer you back within a day or two for new distortion or blur in one eye, and the same day if it is sudden.

For Ayurvedic approaches, see Ayurvedic treatment for macular dystrophy.

NRT is not a treatment for macular dystrophy and does not replace genetic testing, monitoring, low-vision care or clinical trials. If you want to talk through whether integrative care makes sense alongside your care, request a consultation.

Questions people ask

Is macular dystrophy the same as macular degeneration?

No. Macular dystrophies are inherited, caused by a single gene and often start young. Age-related macular degeneration mostly affects people over 55 and has several genetic and lifestyle risk factors. Pattern dystrophy can look like it, which is one reason genetic testing helps [1].

Is there a cure for macular dystrophy?

Not yet. No medicine is approved for most types, though anti-VEGF injections treat leaking vessels when they occur. Several trial drugs are being tested for Stargardt disease [12, 14, 15]. Gene therapies are in research for some types.

What is the most common macular dystrophy?

Stargardt disease, in both adults and children [2]. Best disease is second [1].

What does macular dystrophy in children look like?

A child may struggle to see the board, hold books close or have vision that glasses do not fully correct. In childhood-onset Stargardt disease, symptoms began at about age 10 on average, and damage grew faster than in adult-onset disease [20]. Best disease and X-linked retinoschisis also start young [1], so ask for genetic testing and school vision support early.

What is the prognosis?

It depends on the type. Pattern dystrophy usually keeps good vision, while Stargardt disease that starts early and Sorsby fundus dystrophy tend to cause more central vision loss [1]. Side vision is often kept, though some Stargardt disease and cone-rod dystrophy also affect it [1, 4].

Is there treatment for occult macular dystrophy?

There is no specific treatment yet. Care means a confirmed diagnosis with ERG and genetic testing (RP1L1), low-vision help, and regular review [6].

References

1. Rahman N, Georgiou M, Khan KN, Michaelides M. Macular dystrophies: clinical and imaging features, molecular genetics and therapeutic options. Br J Ophthalmol. 2020;104(4):451-460.
2. Tanna P, Strauss RW, Fujinami K, Michaelides M. Stargardt disease: clinical features, molecular genetics, animal models and therapeutic options. Br J Ophthalmol. 2017;101(1):25-30.
3. Stone EM, Andorf JL, Whitmore SS, et al. Clinically focused molecular investigation of 1000 consecutive families with inherited retinal disease. Ophthalmology. 2017;124(9):1314-1331.
4. Hamel CP. Cone rod dystrophies. Orphanet J Rare Dis. 2007;2:7.
5. Small KW, DeLuca AP, Whitmore SS, et al. North Carolina macular dystrophy is caused by dysregulation of the retinal transcription factor PRDM13. Ophthalmology. 2016;123(1):9-18.
6. Akahori M, Tsunoda K, Miyake Y, et al. Dominant mutations in RP1L1 are responsible for occult macular dystrophy. Am J Hum Genet. 2010;87(3):424-429.
7. Foundation Fighting Blindness. No-cost genetic testing: My Retina Tracker Genetic Testing Program. Accessed 15 Oct 2026.
8. Andreuzzi P, Fishman GA, Anderson RJ. Use of a carbonic anhydrase inhibitor in X-linked retinoschisis: effect on cystic-appearing macular lesions and visual acuity. Retina. 2017;37(8):1555-1561.
9. Stelmack JA, Tang XC, Reda DJ, et al. Outcomes of the Veterans Affairs Low Vision Intervention Trial (LOVIT). Arch Ophthalmol. 2008;126(5):608-617.
10. Radu RA, Yuan Q, Hu J, et al. Accelerated accumulation of lipofuscin pigments in the RPE of a mouse model for ABCA4-mediated retinal dystrophies following vitamin A supplementation. Invest Ophthalmol Vis Sci. 2008;49(9):3821-3829.
11. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119(10):1417-1436.
12. Kay CN, Saad L, DeBartolomeo G, et al. Safety and effects of gildeuretinol acetate on retinal atrophic lesions in Stargardt disease: the TEASE-1 randomized clinical trial. JAMA Ophthalmol. Published online 3 September 2026. doi:10.1001/jamaophthalmol.2026.3662
13. Ophthalmology Times. Phase 3 NORTHSTAR trial launches for gildeuretinol in Stargardt disease. 12 June 2026.
14. Belite Bio. Belite Bio announces positive topline results from the pivotal global phase 3 DRAGON trial of tinlarebant in adolescents with Stargardt disease [press release]. 1 December 2025.
15. Belite Bio. FDA acceptance and priority review of new drug application for tinlarebant for Stargardt disease type 1 [press release, SEC Form 6-K exhibit 99.1]. 11 August 2026.
16. Kubota Vision. Kubota Vision announces post hoc analysis from phase 3 clinical trial of emixustat in patients with Stargardt disease [press release]. 3 October 2022. Trial record: SeaSTAR, ClinicalTrials.gov NCT03772665.
17. MacDonald IM, Sieving PA. Investigation of the effect of dietary docosahexaenoic acid (DHA) supplementation on macular function in subjects with autosomal recessive Stargardt macular dystrophy. Ophthalmic Genet. 2018;39(4):477-486.
18. Piccardi M, Fadda A, Martelli F, et al. Antioxidant saffron and central retinal function in ABCA4-related Stargardt macular dystrophy. Nutrients. 2019;11(10):2461.
19. Kuriyan AE, Albini TA, Townsend JH, et al. Vision loss after intravitreal injection of autologous "stem cells" for AMD. N Engl J Med. 2017;376(11):1047-1053.
20. Georgiou M, Kane T, Tanna P, et al. Prospective cohort study of childhood-onset Stargardt disease: fundus autofluorescence imaging, progression, comparison with adult-onset disease, and disease symmetry. Am J Ophthalmol. 2020;211:159-175.